biote Corp.

Equities

BTMD

US0906831039

Professional Information Services

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
6.35 ^USD	+7.63%		+12.59%	+28.54%

20/05	Biote Shares Fall After Report by Short-Seller J Capital	MT
10/05	Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.	CI

Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 08, 2024 at 01:48 am IST

biote Corp. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 46.8 million compared to USD 44.84 million a year ago.

Net loss was USD 2.07 million compared to USD 6.81 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.39 a year ago. Diluted loss per share from continuing operations was USD 0.06 compared to USD 0.39 a year ago.

Latest news about biote Corp.

Biote Shares Fall After Report by Short-Seller J Capital	20/05	MT
Biote Corp. acquired Certain assets of BioSana ID LLC for $0.8 million.	10/05	CI
Earnings Flash (BTMD) BIOTE Reports Q1 Revenue $46.8M, vs. Street Est of $45.7M	08/05	MT
Transcript : Biote Corp., Q1 2024 Earnings Call, May 07, 2024	08/05
Biote Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Biote Corp. Reaffirms Earnings Guidance for the Year 2024	08/05	CI
B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating	05/04	MT
CORRECTION : --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating	03/04	MT
B. Riley Lowers biote's PT to $4 From $6 After Lower-Than-Expected Q4 2023 Results, Says California Regulations Hit Sales Outlook; Maintains Buy Rating	26/03	MT
Biote Corp. completed the acquisition of Asteria Health.	14/03	CI
Roth MKM Adjusts Price Target on Biote to $9 From $8, Maintains Buy Rating	13/03	MT
Transcript : Biote Corp., Q4 2023 Earnings Call, Mar 12, 2024	13/03
Biote Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03	CI
Biote Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03	CI
Earnings Flash (BTMD) BIOTE Reports Q4 Revenue $45.7M, vs. Street Est of $45.7M	13/03	MT
Biote Corp. Provides Revenue Guidance for 2024	13/03	CI
B. Riley Securities Starts biote With Buy Rating, $9 Price Target	20/02	MT
Jefferies Starts Biote With Buy Rating, $6.55 Price Target	01/02	MT
Tech Stocks Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	26/01	MT
Biote Board Approves $20 Million Share Repurchase Program	26/01	MT
Biote Corp. announces an Equity Buyback for $20 million worth of its shares.	26/01	CI
Biote Corp. authorizes a Buyback Plan.	25/01	CI
Sector Update: Health Care Stocks Mixed Premarket Thursday	18/01	MT
Roth MKM Trims Price Target on Biote to $7 From $8, Maintains Buy Rating	18/01	MT
Sector Update: Health Care	18/01	MT

Chart biote Corp.

Duration

Period

More charts

Company Profile

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Methodâs proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Sector

Professional Information Services

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company